April 02, 2026 03:40 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India | ‘Unsubstantial allegations’: Calcutta HC dismisses plea on ECI’s officer transfers in Bengal | Tennis icon Leander Paes joins BJP ahead of Bengal polls | 8 killed, several injured in crowd crush at Bihar temple in Nalanda | Trump signals exit from Iran war even as Strait of Hormuz remains shut: Report | Mystery death in Pakistan: JeM chief Masood Azhar’s brother found dead
UK COVID19
Pixabay

UK testing new drug to prevent COVID-19 development after Coronavirus contraction: Reports

| @indiablooms | Dec 26, 2020, at 02:33 pm

Moscow/Sputnik: UK scientists are testing a new drug to prevent people, who have been exposed to the coronavirus, from falling ill with COVID-19, media reported.
 

According to The Guardian, the antibody therapy has been developed by the University College London Hospitals and the AstraZeneca pharmaceutical company.

“If we can prove that this treatment works and prevent people who are exposed to the virus going on to develop Covid-19, it would be an exciting addition to the arsenal of weapons being developed to fight this dreadful virus,” virologist Catherine Houlihan, who is leading the study, said, as quoted by The Guardian.

The drug will provide patients with an immediate cocktail of antibodies that may protect them from COVID-19 for 6-12 months.

The medicine may be used as an emergency treatment both to hospital inpatients and care home residents.

The therapy may be also useful for those, who had contact with COVID-19 patients, and students, who live, study and socialize in big communities.

If approved, the drug will be available for public use in March or April.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.